Caerus Investment Advisors LLC Takes Position in Bristol Myers Squibb Company $BMY

Caerus Investment Advisors LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the third quarter, HoldingsChannel reports. The institutional investor bought 13,777 shares of the biopharmaceutical company’s stock, valued at approximately $621,000.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its position in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares during the period. JPL Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $36,000. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $38,000. Finally, Turning Point Benefit Group Inc. acquired a new stake in shares of Bristol Myers Squibb during the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $59.71 on Wednesday. The firm’s 50 day simple moving average is $58.47 and its 200 day simple moving average is $51.64. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a market capitalization of $121.59 billion, a price-to-earnings ratio of 17.31, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BMY shares. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Scotiabank reiterated a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research note on Wednesday, December 3rd. Piper Sandler restated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $61.41.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: HSBC raised its price target on BMY from $53 to $60 and kept a “hold” rating, signaling improved near-term analyst sentiment (though the new PT offers only ~0.5% upside from current levels). Benzinga
• Positive Sentiment: BMY reported that its investigational candidate BMS-986278 advanced through a key heart safety study (Phase 1 update), reducing development risk for that program and supporting pipeline value upside if subsequent data are favorable. TipRanks: BMS-986278 Update
• Neutral Sentiment: Zacks published a piece framing BMY as a strong value stock based on style scores and valuation metrics — a reminder that some investors are viewing BMY as a defensive, income-oriented pick rather than a high-growth biotech. Zacks: Value Stock
• Neutral Sentiment: Recent market commentary notes BMY has slightly outperformed recent market returns, reflecting stability from its commercial portfolio and dividend profile rather than fresh catalysts. Yahoo Finance: Market Performance
• Neutral Sentiment: Analyst comparisons (Pfizer vs. BMY) highlight competition in oncology and pipeline-driven M&A/portfolio moves; these comparisons keep investor focus on relative pipeline strength and strategic deals. Zacks: PFE vs BMY

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.